

#### DEPARTMENT OF THE AIR FORCE 59TH MEDICAL WING (AETC) JOINT BASE SAN ANTONIO - LACKLAND TEXAS



20 MAR 2017

MEMORANDUM FOR SGVT

ATTN: MAJ DARRICK J BECKMAN

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

- Your paper, entitled <u>Developing Clinical Leaders in Primary Care: The US Air Force Diabetes Champion Course</u> presented at/published to <u>Endocrine Society 2017 Meeting</u>, <u>Orlando, FL, (National Conference), 3 April 2017 & SURF San Antonio, TX, 16 June 2017 (Poster & Presentation)</u> in accordance with MDWI 41-108, has been approved and assigned local file #<u>17148</u>.
- 2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
- 3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist's Office, Ms. Alice Houy, office phone: 210-292-8029; email address: alice.houy.civ@mail.mil.
- 4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC Director, Clinical Investigations & Research Support

inda Steel Goodwin

## PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

#### INSTRUCTIONS

### USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

- 1. The author must complete page two of this form:
  - a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D;
     Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed
     Medical Research Program (CDMRP); Grants; etc.]
  - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
- 2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
- Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
- 4. Attach a copy of your abstract, paper, poster and other supporting documentation.
- Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
- 6. On page 2, have either your unit commander, program director or immediate supervisor:
  - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
- 7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.
- 8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
- Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
- 10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.
- 11. The Joint Ethics Regulation (JER) DoD 5500.07-R, Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISG/JAC legal office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.

If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5795/3365, DSN 473.

- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:
  - "The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:
  - "The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02\_AFI 40-402."
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401\_IP:
  - "The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS							
1. TO: CLINICAL RESEARCH 2. FROM: (Auth	nor's Name, Rank, Grade	, Office	Symbol)	3. GME/GHSE	STUDENT:	4. PROTOCOL NUMBER:	
BECKMAN, I	DARRICK J, Maj, O4,	, SGVT	Γ	X YES	□ NO	N/A	
5. PROTOCOL TITLE: (NOTE: For each new re		ch or ted	chnical information as a	publication/pre	esentation, a n	ew 59 MDW Form 3039	
must be submitted for review and approval.)							
Developing Clinical Leaders in Primary Care: The US Air Force Diabetes Champion Course							
6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:							
Developing Clinical Leaders in Primary Care: The US Air Force Diabetes Champion Course							
7. FUNDING RECEIVED FOR THIS STUDY? YES NO FUNDING SOURCE:							
8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES: YES NO							
9. IS THIS MATERIAL CLASSIFIED? YES NO							
10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.?  YES NO NOTE: If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.							
11. MATERIAL IS FOR: ☑ DOMESTIC RELEASE ☐ FOREIGN RELEASE							
CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED.  11a. PUBLICATION/JOURNAL (List intended publication/journal.)							
11b. PUBLISHED ABSTRACT (List intended journal.)							
11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)  Endocrine Society 2017 Meeting - Orlando, FL (National Conference) - 3 Apr 17 / SURF - San Antonio, TX - 16 Jun 17							
11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)							
40. UNIVERSALES							
12. HAVE YOUR ATTACHED RESEARCH/TECHNICAL MATERIALS BEEN PREVIOUSLY APPROVED TO BE PUBLISHED/PRESENTED?							
☐ YES ☑ NO ASSIGNED FILE # DATE							
<ol> <li>EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC NOTE: All publications/presentations are required to be placed in the Defense Technical Information Center (DTIC).</li> </ol>							
DATE							
March 15, 2017							
14. 59 MDW PRIMARY POINT OF CONTACT	ACT (Last Name, First Name, M.I., email)		15. DUTY PHONE/PAGER NUMBER				
BECKMAN, DARRICK, J, darrick.j.beckman.mil@mail.mil				210-916-	-8589/594-0332		
16. AUTHORSHIP AND CO-AUTHOR(S) List in		ar in the	e manuscript.				
LAST NAME, FIRST NAME AND M.I.	GRADE/RANK	S	QUADRON/GROUP/OF	FICE SYMBO	L INST	TITUTION (If not 59 MDW)	
Primary/Corresponding Author     Beckman, Darrick	Maj/O4	9590	959CSPS/SGVT				
b. Folaron, Irene	LtCol/O5		959MDOS/SGO5E				
c. True, Mark	Col/O6	959MDOS/SGO5E					
d. Wardian, Jana	201/00		959MDOS/SGOSE 959 MDSS/DCOE				
					-		
e. Sauerwein, Tom	IIDED / IED DOD 5550 00	959 MDSS/DCOE					
17. IS A 502 ISG/JAC ETHICS REVIEW REQUIRED (JER DOD 5500.07-R)? YES NO I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR							
219, AFMAN 40-401_IP, AND 59 MDWI 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.							
18. AUTHOR'S PRINTED NAME, RANK, GRADE BECKMAN, DARRICK, J, Maj, O4			19. AUTHOR'S SIGNA BECKMAN.DARRICK.J.1260242			20. DATE February 24, 2017	
21. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE FOLARON, IRENE, LtCol, O5			22. APPROVING AUTHORITY'S SIGNATURE FOLARON.IRENE.1145914724 February 24, 2017				

PROCESSING OF PROFES	SSIONAL MEDICAL RI	SEARCH/TECHNICAL PUBLICAT	IONS/PRESENTATIONS			
TST ENDORSEMENT (59 MDW/SGVU Use C	inly)					
TO: Clinical Research Division 59 MDW/CRD	24. DATE RECEIVED	25. ASSIGNED PROCESSING REQ	UEST FILE NUMBER			
Contact 292-7141 for email instructions.	March 09, 2017	17148				
26. DATE REVIEWED		27. DATE FORWARDED TO 502 ISG	S/JAC			
March 17, 2017		,				
28. AUTHOR CONTACTED FOR RECOMME	ENDED OR NECESSARY C	HANGES: NO YES If yes, give date	e. March 14, 2017			
	SAPPROVED					
Educational Program evaluation on diab	etes education. Appropri	ate disclaimers included				
30. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER	31. REVIEWER SIGNATURE	22 DATE			
Kevin Kupferer/GS13/Human Research			32. DATE			
2nd ENDORSEMENT (502 ISG/JAC Use Onl		NOPPEREN.REVIN.R. 108666/2/0 and UNITED A Five a resignary time 2017 (0.17 to 49 24 40 02)	March 17, 2017			
33. DATE RECEIVED	у)	24 PATE FORWARDED TO TO TO TO				
oo. DATE REGEIVED		34. DATE FORWARDED TO 59 MDW	34. DATE FORWARDED TO 59 MDW/PA			
36. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER	37. REVIEWER SIGNATURE	38. DATE			
			155 25.02			
3rd ENDORSEMENT (59 MDW/PA Use Only						
39. DATE RECEIVED		40. DATE FORWARDED TO 59 MDW	40. DATE FORWARDED TO 59 MDW/SGVU			
March 17, 2017	March 17, 2017 March 20, 2017					
41. COMMENTS APPROVED (In comp	oliance with security and poli-	ty review directives.) DISAPPROVE	,			
42. PRINTED NAME, RANK/GRADE, TITLE (	OF REVIEWER	43. REVIEWER SIGNATURE	44. DATE			
Kevin Iinuma, SSgt/E-5, 59 MDW Publi		IINUMA.KEVIN.MITSUGU. 1296227 Digitaly suprad by proteine KEVIN, MITSUGU. 1296227 Digitally suprad by proteine KEVIN, MITSUGU. 13920 Digital Suprad by Structure (STA) Committee of Committee Commit	March 20, 2017			
4th ENDORSEMENT (59 MDW/SGVU Use O						
45. DATE RECEIVED		ENIOR AUTHOR NOTIFIED BY PHONE OF (ES	Control of the contro			
47. COMMENTS APPROVED DIS	APPROVED					
48. PRINTED NAME, RANK/GRADE, TITLE (	OF REVIEWER	49. REVIEWER SIGNATURE	50. DATE			

# BUILDING DIABETES CHAMPIONS IN PRIMARY CARE: THE AIR FORCE EXPERIENCE

Maj Darrick Beckman, M.D.<sup>1</sup>, Col Mark True, M.D.<sup>1</sup>, Jana Wardian, Ph.D., M.S.W.<sup>2</sup>, LtCol (ret) Nina Watson, M.S.N., R.N., C.D.E.<sup>2</sup>, Connie Morrow, M.A.Ed.-A.E.T., C.R.T.<sup>2</sup>, and LtCol (ret) Tom Sauerwein, M.D.<sup>2</sup>

<sup>1</sup>Department of Endocrinology, San Antonio Military Medical Center; <sup>2</sup>Diabetes Center of Excellence, Wilford Hall Ambulatory Surgical Center

The Department of Defense (DoD) provides comprehensive care to over 150K patients with diabetes (active duty, retirees, and dependents) in over 400 clinics worldwide. With only 33 endocrinologists in the DoD, the majority of diabetes care is left to primary care.

The US Air Force Diabetes Center of Excellence designed the Diabetes Champion Course (DCC), a semi-annual, 3-day course, to train primary care teams to become local champions in diabetes standards of care. Didactics and hands-on training are focused on current standards, the latest technologies, and patient flow in a team-based setting. Each team is tasked to identify local deficits and make a Plan of Action (POA) for implementation.

In a process improvement project, we evaluated the impact of this course. We contacted attendees from 43 clinics with POAs from the last 3 courses, and we received 25 responses from 19 clinics. Results were obtained via a semi-structured phone interview to evaluate benefits of and obstacles to POA implementation.

The last 3 courses had 222 participants from 77 clinics: 47 physicians, 23 mid-level providers, 113 nurses, and 39 from other disciplines. Twelve of 19 clinics (63%) were able to implement part or all of their original POAs and 17 of 19 clinics (89%) reported improvements associated with attending the course. Benefits included improving multidisciplinary cooperation, routine screenings (labs, foot exams, ophthalmology), and documentation; setting up a diabetes education class; and increasing collaboration between the 3 military services. Common obstacles to POA implementation were turnover of staff, lack of time and resources, provider resistance, and lack of leadership support.

The DCC provides the expert-driven guidance and tools to primary care clinical teams to increase adherence to diabetes standards and appropriately leverages the limited number of endocrinologists in the DoD. The DCC will continue to be modified to address common barriers to maximize impact.

The views expressed are those of the authors and do not reflect the official views or policy of the Department of Defense, or its Components.